NCT04789200View on ClinicalTrials.gov

Phase 2 Study of NX9 for Delineation of Bowel Anatomy

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

August 1, 2020

Primary Completion Date

November 1, 2021

Study Completion Date

December 1, 2021

Conditions
GI CarcinomaGI Disorders
Interventions
DRUG

NX9 Oral Contrast Agent

Distension and marking of the bowel lumen will be compared between the 1st and 2nd scan. Ability to see IV contrast enhancement will be assessed on the 3rd scan in relationship to the 2nd scan.

Trial Locations (2)

55905

Mayo Clinic, Rochester

98109

University of Washington, Seattle

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Nextrast, Inc.

INDUSTRY

NCT04789200 - Phase 2 Study of NX9 for Delineation of Bowel Anatomy | Biotech Hunter | Biotech Hunter